Justin Watts, MD
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy (NCT06782542) | Justin Watts, MD | 2026-03-31 |
| Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS (NCT03459859) | Justin Watts, MD | 2018-05-21 |
Track Justin Watts, MD automatically
Every clearance here is in the API, with alerts when new ones post.